Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL873126 | 1.00 | CYP11B1 (0.31) | CYP11B1CYP11B2 | |
| SCHEMBL16877709 | 1.00 | CYP11B1 (0.31) | CYP11B1CYP11B2 | |
| SCHEMBL5641872 | 0.97 | — | — | |
| SCHEMBL16877662 | 0.91 | — | — | |
| SCHEMBL21863849 | 0.88 | ALDH1A1 (0.39) | — | |
| SCHEMBL21844964 | 0.88 | ALDH1A1 (0.32) | — | |
| SCHEMBL8157303 | 0.88 | ALDH1A1 (0.32) | — | |
| SCHEMBL15568858 | 0.88 | CYP11B1 (0.30) | CYP11B1CYP11B2 | |
| SCHEMBL1864864 | 0.87 | — | — | |
| SCHEMBL16877902 | 0.86 | ALDH1A1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120118088-A | Myt1 kinase inhibitor compounds, pharmaceutical compositions thereof and uses thereof | 广东东阳光药业股份有限公司 | 2025-06-10 | — | — | CN | claimed |
| US-20240360081-A1 | SULFONAMIDE OREXIN RECEPTOR AGONISTS AND USES THEREOF | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-10-31 | — | — | US | claimed |
| EP-4359387-A1 | SULFONAMIDE OREXIN RECEPTOR AGONISTS AND USES THEREOF | Jazz Pharmaceuticals Ireland Limited (IE) | 2024-05-01 | — | — | EP | claimed |
| CN-117769542-A | Sulfonamide orexin receptor agonists and uses thereof | 爵士制药爱尔兰有限公司 | 2024-03-26 | — | — | CN | claimed |
| WO-2022269049-A1 | SULFONAMIDE OREXIN RECEPTOR AGONISTS AND USES THEREOF | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2022-12-29 | — | — | WO | claimed |
| US-20040254158-A1 | Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-16 | — | — | US | claimed |
| CN-120118088-A | Myt1 kinase inhibitor compounds, pharmaceutical compositions thereof and uses thereof | 广东东阳光药业股份有限公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-116033828-B | Heterocyclic derivatives as pest control agents | 拜耳公司 | 2025-05-16 | — | — | CN | disclosed |
| US-20240417486-A1 | ASYMMETRIC BIS-BENZIMIDAZOLE STING AGONIST IMMUNOCONJUGATES AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2024-12-19 | — | — | US | disclosed |
| US-20240360081-A1 | SULFONAMIDE OREXIN RECEPTOR AGONISTS AND USES THEREOF | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-10-31 | — | — | US | disclosed |
| EP-4412660-A1 | ASYMMETRIC BIS-BENZIMIDAZOLE STING AGONIST IMMUNOCONJUGATES AND USES THEREOF | Bolt Biotherapeutics, Inc. (US) | 2024-08-14 | — | — | EP | disclosed |
| CN-118265545-A | Asymmetric bisbenzimidazole STING agonist immunoconjugates and uses thereof | 博尔特生物治疗药物有限公司 | 2024-06-28 | — | — | CN | disclosed |
| EP-4359387-A1 | SULFONAMIDE OREXIN RECEPTOR AGONISTS AND USES THEREOF | Jazz Pharmaceuticals Ireland Limited (IE) | 2024-05-01 | — | — | EP | disclosed |
| EP-2121656-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | Pfizer Products Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080287479-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER INC | 2008-11-20 | — | — | US | disclosed |
| WO-2008084300-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER PRODUCTS INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| US-7312214-B2 | 1, 1-disubstituted cycloalkyl derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-07-19 | — | — | US | disclosed |
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-07-19 | — | — | US | disclosed |
| US-20040254158-A1 | Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287479-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | SPTLC1, SPTLC2, CPT1A | CYP11B1 262/4885CYP11B2 360/4885 |
| US-20240417486-A1 | ASYMMETRIC BIS-BENZIMIDAZOLE STING AGONIST IMMUNOCONJUGATES AND USES THEREOF | STING1, BID, MAVS | CYP11B1 2165/4885CYP11B2 2510/4885 |
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | CNR1, CNR2, OPRD1 | CYP11B1 412/4885CYP11B2 554/4885 |
| US-20240360081-A1 | SULFONAMIDE OREXIN RECEPTOR AGONISTS AND USES THEREOF | HCRTR1, HCRTR2, NPY1R | CYP11B1 584/4885CYP11B2 581/4885 |
| US-20040254158-A1 | Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders | SERPINC1, PCSK9, PLAT | CYP11B1 475/4885CYP11B2 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.